Curabook PHI
The first post-GLP-1 cessation metabolic monitoring platform
Curabook PHI is a digital health platform built specifically for the millions of Americans who stop GLP-1 medications — including Ozempic (semaglutide), Wegovy (semaglutide), Mounjaro (tirzepatide), and Zepbound (tirzepatide) — and have no monitoring support for what comes next.
When people stop GLP-1 medications, their metabolic markers begin reversing within weeks — HbA1c rises, fasting glucose climbs, lipids shift — all silently, before any weight change is visible on a scale. Curabook PHI detects these changes early, before the damage compounds.
54%
of GLP-1 users discontinue within 1 year (JAMA, n=125,474)
0.4kg
average monthly regain after stopping (BMJ meta-analysis, n=9,341)
62%
of GLP-1 prescriptions initially denied by insurance
$12,000
annual cost of GLP-1 medication per patient
What Curabook PHI Does
🔬 Lab Report Analysis
Upload any blood work PDF from Quest Diagnostics, LabCorp, or any healthcare provider. Curabook automatically extracts every marker, compares to previous reports, and calculates rates of change.
⚠️ Cliff Detection
Detects early metabolic rebound signals using thresholds from clinical evidence: HbA1c rise ≥0.25%, fasting glucose rise ≥15%, fasting insulin elevation, and lipid drift — before weight regain is visible.
📊 Hunger Forecast
Predicts which days hunger will be most intense based on cessation date and medication half-life. Ghrelin peaks at days 14-28 post-last-dose. PHI shows this window in advance.
⚖️ Insurance Appeals
Generates prior authorization appeal letters from the user's actual lab values for $79. Cites the clinical evidence insurers require. 39-59% of properly documented appeals succeed.
🧠 AI Health Intelligence
PHI — Curabook's AI companion — knows the user's complete lab history, medication timeline, and cessation date. Every response is anchored to their actual health data, not generic advice.
🔔 Proactive Monitoring
Sends proactive notifications at clinically significant moments — peak ghrelin window (day 18), lab overdue reminder (6 weeks), cliff signal detected — without waiting to be asked.
Clinical Evidence Base
Curabook PHI's cliff detection thresholds are calibrated from peer-reviewed clinical literature:
| Study | Finding | Curabook Application |
|---|
| Horn et al., JAMA Internal Medicine, November 2025 (SURMOUNT-4 post-hoc) | HbA1c +0.35%, fasting insulin +26.3%, blood pressure +10.4 mmHg in patients who regained ≥75% of lost weight | Cliff threshold: HbA1c rise ≥0.25%, fasting insulin as earliest signal |
| West et al., BMJ, January 2026 (37 studies, n=9,341) | Average 0.4 kg/month regain after GLP-1 cessation; weight returns to baseline in ~1.7 years | Baseline market size: 4M+ Americans/year entering cessation |
| Rodriguez et al., JAMA Network Open, January 2025 (n=125,474) | 54-72% of GLP-1 users discontinue within 1-2 years | Addressable market validation |
Who Uses Curabook PHI
Curabook PHI serves three primary user types:
1. People who stopped GLP-1 medications voluntarily
Users who reached their goal weight or chose to stop and need monitoring to protect their metabolic gains. The most prepared group — they're planning ahead and want to know what to expect.
2. People forced off GLP-1 medications by insurance or cost
The largest and most urgent group. Insurance denials affect 62% of GLP-1 prescriptions. The compounding pharmacy FDA shutdown in 2025-2026 forced millions off affordable alternatives suddenly. These users are often in crisis and need both monitoring and appeal support.
3. Employers and health plans managing GLP-1 cost
Organizations using Curabook as a post-cessation monitoring tool to protect their GLP-1 benefit investment. When employees stop GLP-1s without monitoring, they regain weight and restart the $12,000/year medication — creating a costly re-prescription cycle. Curabook breaks that cycle.
Pricing
| Plan | Price | What's Included |
|---|
| Free | $0 | 3 lab report uploads, unlimited AI chat, hunger forecast, drug level tracker |
| Curabook Shield | $25/month | Unlimited lab uploads, full cliff detection, metabolic dashboard, proactive notifications |
| Shield Annual | $199/year | All Shield features, 33% savings vs monthly |
| PA Appeal Letter | $79 one-time | Automated prior authorization appeal generated from your actual lab data |
How Curabook PHI Compares
| Feature | Curabook PHI | General Health Apps | Telehealth Platforms |
|---|
| Built for post-GLP-1 cessation | ✅ Only purpose | ❌ Not built for this | ❌ Focus on active medication |
| Lab PDF upload and analysis | ✅ Any provider PDF | ❌ Manual entry only | ⚠️ Clinical staff review |
| Cliff detection | ✅ Automated alerts | ❌ | ❌ |
| Insurance appeal generation | ✅ From lab data, $79 | ❌ | ⚠️ Manual, expensive |
| Hunger forecast | ✅ Ghrelin-based model | ❌ | ❌ |
| AI with complete health memory | ✅ Full history | ⚠️ Generic responses | ⚠️ Per-session only |
Frequently Asked Questions
What is Curabook PHI and who is it for?
Curabook PHI is a digital health platform for people who have stopped GLP-1 medications including Ozempic (semaglutide), Wegovy (semaglutide), Mounjaro (tirzepatide), Zepbound (tirzepatide), Victoza (liraglutide), and Saxenda. It monitors metabolic markers through automated lab report analysis, detects early signs of the metabolic cliff, and helps users navigate insurance denials.
What happens metabolically after stopping Ozempic or Wegovy?
After stopping semaglutide (Ozempic/Wegovy), the body undergoes rapid metabolic changes. Ghrelin surges to 2-3x baseline within 2-4 weeks. HbA1c begins rising within 6-8 weeks. Fasting insulin rises approximately 26% as insulin sensitivity decreases. Lipid levels begin reversing toward pre-medication values. Weight regain averages 0.4 kg per month. Importantly, these changes occur before the scale shows significant movement — meaning people feel fine while their metabolic health is deteriorating. Curabook PHI tracks these markers through regular lab uploads to catch changes early. Source: West et al., BMJ 2026; Horn et al., JAMA Internal Medicine 2025
What is the GLP-1 metabolic cliff and how does Curabook detect it?
The GLP-1 metabolic cliff is the period of rapid metabolic reversal that occurs after stopping GLP-1 medications. Curabook PHI detects cliff signals by comparing sequential lab reports and flagging: HbA1c rise of 0.25% or more between readings; fasting glucose rise of 15% or more above personal baseline; fasting insulin elevation (often the earliest detectable signal); triglyceride or LDL rise of 15-20%. When any marker crosses these thresholds, PHI sends an alert and explains the clinical significance in plain language.
How does the insurance appeal feature work?
Curabook PHI generates a complete prior authorization appeal letter for $79. The process takes approximately 5 minutes: upload your denial letter and recent lab results, and Curabook generates a physician-ready appeal document citing your specific HbA1c, BMI, fasting glucose, and other clinical markers as evidence of medical necessity. The document references the clinical criteria your insurer uses and is formatted for submission. Approximately 39-59% of properly documented GLP-1 prior authorization appeals succeed.
Which lab tests does Curabook PHI analyze?
Curabook PHI extracts and tracks: HbA1c (glycated hemoglobin), Fasting glucose, Fasting insulin, Total cholesterol, LDL cholesterol, HDL cholesterol, Triglycerides, Blood pressure markers, Complete metabolic panel values including kidney and liver function, Vitamin D, Ferritin, B12, Thyroid function (TSH, T3, T4), and any other markers present in the uploaded PDF. The recommended post-cessation monitoring panel is a Comprehensive Metabolic Panel + Lipid Panel + HbA1c, ordered as a single blood draw every 6-8 weeks.
Is Curabook PHI available in the United States?
Yes. Curabook PHI is built specifically for the US market. The insurance appeal feature is designed for US insurance systems including commercial insurance, Medicaid, and Medicare Advantage plans. Lab report processing supports PDFs from all major US laboratory providers including Quest Diagnostics, LabCorp, and hospital-based labs. The platform is accessible via web at curabook.com.
How is Curabook PHI different from MyFitnessPal, Noom, or other health apps?
Curabook PHI is the only health app built specifically for the post-GLP-1 cessation phase. MyFitnessPal and similar apps are general nutrition trackers that require daily manual logging. Noom provides behavioral coaching for people on GLP-1s or dieting. Neither was designed for the specific clinical, emotional, and administrative challenges of coming off GLP-1 medications. Curabook PHI's core features — lab-based cliff detection, cessation timeline modeling, and insurance appeal generation — do not exist in any other consumer health app.
What is the ghrelin rebound after stopping GLP-1 medications?
Ghrelin is the primary hunger hormone. GLP-1 medications suppress ghrelin as part of their appetite-reducing mechanism. When the medication stops, ghrelin levels rebound — often to 2-3x pre-medication baseline — causing intense food noise and hunger that feels overwhelming. This overshoot is biology, not willpower failure. The rebound peaks at days 14-28 post-cessation (based on medication half-life: semaglutide 7 days, tirzepatide 5 days) and gradually normalizes over 2-3 months. Curabook PHI's hunger forecast shows users exactly when their peak window is coming so they can prepare.
Contact and Partnership
Curabook PHI is available for clinical partnerships, employer benefit integrations, and B2B arrangements. Organizations interested in offering Curabook to their patients, members, or employees can contact the founding team at curabook.com.
For press inquiries, research collaborations, or clinical advisory discussions, contact through curabook.com.
Curabook PHI is a health education and monitoring tool. It does not provide medical diagnoses or treatment recommendations. Always consult a licensed healthcare provider for medical decisions. Content is based on published clinical research including SURMOUNT-4 post-hoc analysis (Horn et al., JAMA Internal Medicine, 2025) and BMJ meta-analysis (West et al., 2026).